Biofrontera Inc. (BFRIW)

Market Cap	7.45M
Revenue (ttm)	37.32M
Net Income (ttm)	-17.76M
Shares Out	8.87M
EPS (ttm)	-3.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,250
Open	0.0459
Previous Close	0.0457
Day's Range	0.0459 - 0.0459
52-Week Range	0.0459 - 0.0459
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 7, 2025

About BFRIW

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severit...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2015
• Employees: 93
• Stock Exchange: NASDAQ
• Ticker Symbol: BFRIW
• Website: https://www.biofrontera-us.com

Financial Performance

In 2024, Biofrontera's revenue was $37.32 million, an increase of 9.54% compared to the previous year's $34.07 million. Losses were -$17.76 million, -11.78% less than in 2023.